Test Development Engineer Co-op

ZOLL, an Asahi Kasei company manufacturing medical devices, has announced that its Zenix monitor/defibrillator received approval under the European Union Medical Device Regulation 2017/745. The device is designed for use in both emergency medical services and hospital settings. Zenix features a large touchscreen and on-the-fly customisation capabilities, allowing healthcare professionals to make real-time adjustments during critical situations. The device incorporates ZOLL's Real BVM Help and Real CPR Help technology, providing clinical feedback to improve ventilation quality and CPR delivery. According to Elijah White, president of ZOLL Acute Care Technology, virtually all device functions are accessible with three screen-touches or fewer. Zenix joins ZOLL's existing portfolio of professional monitors and defibrillators, including the X Series, R Series and M2 models.

ZOLL medical appoints Eric Knudsen as new CEO. CHELMSFORD, Mass. - (BUSINESS WIRE) - ZOLL(R), an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has appointed Eric Knudsen as its new Chief Executive Officer, effective April 1. Knudsen will succeed Jon Rennert, who served as ZOLL's CEO for the past 10 years and will assume a new role as Executive Chairman of ZOLL's Board of Directors. "As a global leader in medical technology, ZOLL is continually looking for ways to expand our business and reach more patients in need," said Rennert. "Eric has played a unique role in developing our growth strategies and driving our expansion, and I am confident he will lead ZOLL to even greater growth and success." "I am honored to become ZOLL's next CEO," said Knudsen. "ZOLL has a long legacy of innovation and clinical excellence, and today our medical devices, software, and related services are used worldwide to diagnose and treat patients suffering from serious cardiopulmonary and respiratory conditions. We will continue to lead with our commitment to patients and customers and our passion for improving outcomes and helping save lives." Knudsen has nearly 30 years of experience in the medtech industry, with deep expertise in business development and corporate strategy. He led ZOLL's Corporate Development team for six years and was responsible for investing in strategic relationships and acquiring more than a dozen new technologies. For the past four years, Knudsen was President of ZOLL Itamar, a division of ZOLL that is focused on the diagnosis of sleep disorders. Knudsen led the division through significant growth and a dramatic increase in profitability. Prior to joining ZOLL in 2013, Knudsen held leadership positions in international sales, marketing, and manufacturing partnerships at Covidien (now Medtronic), Aspect Medical Systems, and LeMaitre Vascular. He has an MBA from the Thunderbird School of Global Management and a bachelor's degree from Boston College. Rennert was named CEO of ZOLL in 2016, after serving as President of the company's largest business unit for eight years. Under Rennert's leadership as CEO, ZOLL expanded its reach as a global leader in external defibrillation, pioneered novel solutions for patients with serious cardiopulmonary and respiratory conditions, and significantly broadened its portfolio of products. About ZOLL ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions. For more information, visit www.zoll.com. About Asahi Kasei The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With 50,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world's challenges through its three business sectors of Healthcare, Homes, and Material. Its healthcare operations include devices and systems for critical care, products and services for the manufacture of biotherapeutics, and a growing portfolio of specialty pharmaceuticals. For more information, visit www.asahi-kasei.com. Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/. Matt Hogan ZOLL 978-805-6561 [email protected]